Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roloff Gregory W, Aldoss Ibrahim, Kopmar Noam E, Lin Chenyu, Dekker Simone E, Gupta Vishal K, O'Connor Timothy E, Jeyakumar Nikeshan, Muhsen Ibrahim N, Valtis Yannis, Ahmed Naveed, Zhang Amy, Miller Katharine, Dykes Kaitlyn C, Ahmed Mohamed, Chen Evan C, Mercadal Santiago, Schwartz Marc, Tracy Sean I, Dholaria Bhagirathbhai, Mukherjee Akash, Battiwalla Minoo, Logan Aaron C, Ladha Abdullah, Guzowski Caitlin, Hoeg Rasmus T, Hilal Talal, Moore Jozal, Connor Matthew P, Hill LaQuisa C, Tsai Stephanie B, Sasine Joshua P, Solh Melhem M, Kota Vamsi K, Koura Divya, Veeraputhiran Muthu, Leonard Jessica T, Frey Noelle V, Park Jae H, Luskin Marlise R, Bachanova Veronika, Galal Ahmed, Pullarkat Vinod, Stock Wendy, Cassaday Ryan D, Shah Bijal D, Faramand Rawan, Muffly Lori, ROCCA Consortium
Аннотация
METHODS: We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
RESULTS: At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy.
CONCLUSION: Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.